17919232

Source:http://linkedlifedata.com/resource/pubmed/id/17919232

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0002199, umls-concept:C0016360, umls-concept:C0087111, umls-concept:C0205179, umls-concept:C0205195, umls-concept:C0205296, umls-concept:C1280500, umls-concept:C1561451, umls-concept:C2239176, umls-concept:C2348205
pubmed:issue	9
pubmed:dateCreated	2007-10-8
pubmed:abstractText	Intra-arterial 5-fluorouracil (5-FU) plus interferon (IFN) combination therapy is effective against advanced hepatocellular carcinoma (HCC) with portal vein tumour thrombosis. In this study, we compared the efficiency and safety of recombinant IFN-alpha-2b with natural IFN-alpha as components of the combination therapy.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101160857
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil, http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	1478-3223
pubmed:author	pubmed-author:AikataHiroshiH, pubmed-author:ChayamaKazuakiK, pubmed-author:HiramatsuAkiraA, pubmed-author:ItoKatsuhideK, pubmed-author:JeongSoo CheolSC, pubmed-author:KawakamiYoshiikuY, pubmed-author:KodamaHideakiH, pubmed-author:MikiDaikiD, pubmed-author:ShirakawaHirooH, pubmed-author:TakahashiShoichiS, pubmed-author:TakakiShintaroS, pubmed-author:ToyotaNaoyukiN, pubmed-author:UkaKiminoriK
pubmed:issnType	Print
pubmed:volume	27
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1209-16
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:17919232-Adult, pubmed-meshheading:17919232-Aged, pubmed-meshheading:17919232-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:17919232-Carcinoma, Hepatocellular, pubmed-meshheading:17919232-Cost-Benefit Analysis, pubmed-meshheading:17919232-Disease-Free Survival, pubmed-meshheading:17919232-Drug Therapy, Combination, pubmed-meshheading:17919232-Female, pubmed-meshheading:17919232-Fluorouracil, pubmed-meshheading:17919232-Humans, pubmed-meshheading:17919232-Infusions, Intra-Arterial, pubmed-meshheading:17919232-Interferon-alpha, pubmed-meshheading:17919232-Liver Neoplasms, pubmed-meshheading:17919232-Male, pubmed-meshheading:17919232-Middle Aged, pubmed-meshheading:17919232-Prognosis, pubmed-meshheading:17919232-Prospective Studies, pubmed-meshheading:17919232-Recombinant Proteins, pubmed-meshheading:17919232-Survival Rate, pubmed-meshheading:17919232-Therapeutic Equivalency
pubmed:year	2007
pubmed:articleTitle	Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
pubmed:affiliation	Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
pubmed:publicationType	Journal Article